Correlation Between Krystal Biotech and PTC Therapeutics

Can any of the company-specific risk be diversified away by investing in both Krystal Biotech and PTC Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krystal Biotech and PTC Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Krystal Biotech and PTC Therapeutics, you can compare the effects of market volatilities on Krystal Biotech and PTC Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krystal Biotech with a short position of PTC Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krystal Biotech and PTC Therapeutics.

Diversification Opportunities for Krystal Biotech and PTC Therapeutics

-0.15

Correlation Coefficient

Krystal Biotech  PTC Therapeutics

Good diversification

The 3 months correlation between Krystal and PTC is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Krystal Biotech and PTC Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PTC Therapeutics and Krystal Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krystal Biotech are associated (or correlated) with PTC Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PTC Therapeutics has no effect on the direction of Krystal Biotech i.e., Krystal Biotech and PTC Therapeutics go up and down completely randomly.

Pair Corralation between Krystal Biotech and PTC Therapeutics

Given the investment horizon of 90 days Krystal Biotech is expected to generate 4.82 times less return on investment than PTC Therapeutics. But when comparing it to its historical volatility, Krystal Biotech is 1.49 times less risky than PTC Therapeutics. It trades about 0.05 of its potential returns per unit of risk. PTC Therapeutics is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  3,341  in PTC Therapeutics on August 31, 2024 and sell it today you would earn a total of  1,170  from holding PTC Therapeutics or generate 35.02% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Krystal Biotech  vs.  PTC Therapeutics

Krystal Biotech

Risk-Adjusted Performance

3 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Krystal Biotech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Krystal Biotech may actually be approaching a critical reversion point that can send shares even higher in December 2024.

PTC Therapeutics

Risk-Adjusted Performance

11 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in PTC Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental indicators, PTC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Krystal Biotech and PTC Therapeutics

The main advantage of trading using opposite Krystal Biotech and PTC Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krystal Biotech position performs unexpectedly, PTC Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PTC Therapeutics will offset losses from the drop in PTC Therapeutics' long position.

The idea behind Krystal Biotech and PTC Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.